Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Zhang, Tingrui; Tai, Zongguang; Miao, Fengze; Zhang, Xinyue; Li, Jiadong; Zhu, Quangang; Wei, Hua; Chen, Zhongjian

doi:10.1016/j.jconrel.2024.02.033

Journal of Controlled Release

2024

DOI: 10.1016/j.jconrel.2024.02.033

|View full text |Cite

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Tingrui Zhang,

Zongguang Tai,

Fengze Miao

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 395 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Lin,

Yang,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Lin,

Yang,

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions

Zhao,

Wen,

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Zhang,

Huang

2024

J Hematol Oncol

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due to complex manufacturing processes, limited in vivo persistence, and transient therapeutic effects. In vivo CAR-immune cells induced by gene delivery systems loaded with CAR genes and gene-editing tools have shown efficiency for anti-tumor immunotherapy. In situ programming of autologous immune cells avoids the safety concerns of allogeneic immune cells, and the manufacture of gene delivery systems could be standardized. Therefore, the in vivo editing and in situ generation of CAR-immune cells might potentially overcome the abovementioned limitations of current CAR cell therapy. This review mainly focuses on CAR structures, gene-editing tools, and gene delivery techniques applied in anti-tumor immunotherapy to help design and develop in situ CAR-immune cell therapy. The recent applications of in vivo CAR-immune cell therapy in both hematologic malignancies and solid tumors are investigated. To sum up, the in vivo editing and in situ generation of CAR therapy holds promise for offering a practical, cost-effective, efficient, safe, and widely applicable approach to the next-generation anti-tumor immunotherapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Cited by 4 publications

References 395 publications

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies

Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Contact Info

Product

Resources

About